Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia

Harvey, Philip D.; Siu, Cynthia; Loebel, Antony

doi:10.1016/j.scog.2016.05.002

Cited by 8 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent results across the studies demonstrated that if not all, the majority of schizophrenia patients perform more poorly than healthy controls (Mesholam-Gately et al, 2009 ). In accordance with Harvey (Harvey, 1997 ), the depth of the deficit can be described relatively to the corresponding reduction of performance in the number of SDs compared to the population norm and the number of affected functions as following: “mild,” 0.5–1.0 SD, perceptual capacity, remote memory; “moderate,” 1.0–2.0, remote, short and working memory, attention, and visuomotor functions; and “severe cognitive disability,” 2.0–5.0 SD, learning, executive function, memory, vigilance, motor functions, verbal fluency). Subgroups of individuals with SZ may cluster together according to their pattern of cognitive deficits, suggesting the existence of subtypes of dysfunction (Rodriguez et al, 2015 ).…”

Section: Introductionmentioning

confidence: 69%

Theoretical Modeling of Cognitive Dysfunction in Schizophrenia by Means of Errors and Corresponding Brain Networks

et al. 2018

View full text Add to dashboard Cite

The current evidence of cognitive disturbances and brain alterations in schizophrenia does not provide the plausible explanation of the underlying mechanisms. Neuropsychological studies outlined the cognitive profile of patients with schizophrenia, that embodied the substantial disturbances in perceptual and motor processes, spatial functions, verbal and non-verbal memory, processing speed and executive functioning. Standardized scoring in the majority of the neurocognitive tests renders the index scores or the achievement indicating the severity of the cognitive impairment rather than the actual performance by means of errors. At the same time, the quantitative evaluation may lead to the situation when two patients with the same index score of the particular cognitive test, demonstrate qualitatively different performances. This may support the view why test paradigms that habitually incorporate different cognitive variables associate weakly, reflecting an ambiguity in the interpretation of noted cognitive constructs. With minor exceptions, cognitive functions are not attributed to the localized activity but eventuate from the coordinated activity in the generally dispersed brain networks. Functional neuroimaging has progressively explored the connectivity in the brain networks in the absence of the specific task and during the task processing. The spatio-temporal fluctuations of the activity of the brain areas detected in the resting state and being highly reproducible in numerous studies, resemble the activation and communication patterns during the task performance. Relatedly, the activation in the specific brain regions oftentimes is attributed to a number of cognitive processes. Given the complex organization of the cognitive functions, it becomes crucial to designate the roles of the brain networks in relation to the specific cognitive functions. One possible approach is to identify the commonalities of the deficits across the number of cognitive tests or, common errors in the various tests and identify their common “denominators” in the brain networks. The qualitative characterization of cognitive performance might be beneficial in addressing diffuse cognitive alterations presumably caused by the dysconnectivity of the distributed brain networks. Therefore, in the review, we use this approach in the description of standardized tests in the scope of potential errors in patients with schizophrenia with a subsequent reference to the brain networks.

show abstract

Section: Introductionmentioning

confidence: 69%

Theoretical Modeling of Cognitive Dysfunction in Schizophrenia by Means of Errors and Corresponding Brain Networks

et al. 2018

View full text Add to dashboard Cite

show abstract

“…51 One study suggested that lurasidone may be better than quetiapine for cognitive symptoms. 52 Benzodiazepines and anticholinergics for the treatment of parkinsonian side effects should be avoided in the long term. Cognitive remediation [53][54][55] and aerobic exercise 56,57 have shown benefits, but availability and adherence/ persistence can be an issue.…”

Section: Personalised Medicinementioning

confidence: 99%

Finding the Right Setting for the Right Treatment During the Acute Treatment of Individuals with Schizophrenia: A Narrative Review and Clinical Practice Guideline

Correll,

Arango,

Fagiolini

et al. 2024

NDT

View full text Add to dashboard Cite

“…11 Harvey et al have reported that lurasidone improves cognitive and functional performance of patients, and the effects can be expected in long-term treatment rather than short-term. [38][39][40] High doses (≧120 mg) of lurasidone are effective for overall cognitive function, whereas even low doses (≦80 mg) may be effective in improving specific cognitive functions. [38][39][40] Moreover, a long-term improvement of cognitive function was observed in a trial of lurasidone in patients with treatment-resistant schizophrenia, 41 which demonstrated that 24-week treatment with lurasidone improved the PANSS total score and 2 of 7 cognitive domains (speed of processing and executive function).…”

Section: Long-term Studiesmentioning

confidence: 99%

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy

Miura,

Horikoshi,

Ichinose

et al. 2023

DDDT

View full text Add to dashboard Cite

This review aims to provide a comprehensive overview of the current literature on the drug design, development, and therapy of lurasidone for the treatment of schizophrenia. Lurasidone has antagonistic effects on the dopamine D 2 , 5-hydroxytryptamine (5-HT) 2A , and 5-HT 7 receptors and a partial agonistic effect on the 5-HT 1A receptor with low affinities for muscarinic M 1 , histamine H 1 , and a 1 adrenergic receptors. The receptor-binding profile of lurasidone is thought to be associated with fewer side effects such as anticholinergic effects, lipid abnormalities, hyperglycemia, and weight gain. Behavioral pharmacological studies have demonstrated that lurasidone exerts anxiolytic and antidepressive effects and improves cognitive function, which are associated with the modulation of 5-HT 7 and 5-HT 1A receptors. Literature search using PubMed was performed to find published studies of randomized controlled trials and recent meta-analyses regarding efficacy and safety, particularly metabolic side effects of lurasidone in schizophrenia. In short-term studies, the results of randomized placebo-controlled trials and meta-analyses have suggested that lurasidone was superior to placebo in improving total psychopathology, positive symptoms, negative symptoms, and general psychopathology in patients with acute schizophrenia. Regarding safety, lurasidone had minimal metabolic side effects, and was identified as one of the drugs with the most benign profiles for metabolic side effects. Long-term trials revealed that lurasidone had the preventive effects on relapse, with minimal effects on weight gain and other metabolic side effects. Furthermore, lurasidone improves cognitive and functional performance of patients with schizophrenia, especially in long-term treatment. Patients with schizophrenia require long-term treatment with antipsychotics for relapse prevention; thus, minimizing weight gain and other side effects is crucial. Lurasidone is suitable as one of the first-line antipsychotic drugs in the acute phase, and a switching strategy should be considered during the maintenance phase, to balance efficacy and adverse effects and achieve favorable outcomes in the long-term course of schizophrenia.

show abstract

Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia

Cited by 8 publications

References 20 publications

Theoretical Modeling of Cognitive Dysfunction in Schizophrenia by Means of Errors and Corresponding Brain Networks

Theoretical Modeling of Cognitive Dysfunction in Schizophrenia by Means of Errors and Corresponding Brain Networks

Finding the Right Setting for the Right Treatment During the Acute Treatment of Individuals with Schizophrenia: A Narrative Review and Clinical Practice Guideline

Lurasidone for the Treatment of Schizophrenia: Design, Development, and Place in Therapy

Contact Info

Product

Resources

About